<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04440774</url>
  </required_header>
  <id_info>
    <org_study_id>CHIKA01</org_study_id>
    <nct_id>NCT04440774</nct_id>
  </id_info>
  <brief_title>Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.</brief_title>
  <official_title>A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate the Safety &amp; Immunogenicity of the Candidate Chikungunya Vaccine ChAdOx1 Chik &amp; the Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise&#xD;
      dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate&#xD;
      ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in&#xD;
      co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan&#xD;
      area of Monterrey (Mexico), will be recruited as participants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1&#xD;
      Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration,&#xD;
      and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12&#xD;
      participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo&#xD;
      administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered&#xD;
      contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika&#xD;
      administered contralaterally. Group 10 will receive placebo in both arms.&#xD;
&#xD;
      Enrolment into this study will be implemented in a step-wise dose escalation manner.&#xD;
      Participants will be first recruited into the vaccination groups at the lowest dose (Groups&#xD;
      1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory&#xD;
      interim clinical safety reviews that participants will be enrolled into the mid dose groups&#xD;
      (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be&#xD;
      enrolled last, after completion and interim clinical safety reviews from the mid dose groups.&#xD;
      Participants allocated to the Placebo group (Group 10) will be evenly distributed across the&#xD;
      dose escalation model.&#xD;
&#xD;
      Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of&#xD;
      the four intervention arms.&#xD;
&#xD;
      The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken&#xD;
      for 6 months after vaccination day&#xD;
&#xD;
      Innovate UK (project number 971557)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Actual">February 18, 2022</completion_date>
  <primary_completion_date type="Actual">February 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of local reactogenicity signs and symptoms</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of solicited systemic reactogenicity signs and symptoms</measure>
    <time_frame>7 days post vaccination</time_frame>
    <description>Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of unsolicited adverse events</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>Occurrence of unsolicited adverse events for 28 days following vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants through standard blood tests (full blood count, liver and kidney function tests)</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>Change from baseline for safety laboratory measures (haematology and biochemistry blood results)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of serious adverse events during the whole study duration</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>Occurrence of serious adverse events during the whole study duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via PRNT50</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>Plaque-reduction neutralisation tests at 50% (PRNT50) against chikungunya and Zika virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via IgG ELISA antibody titres</measure>
    <time_frame>6 months post vaccination</time_frame>
    <description>IgG ELISA antibody titres against proteins of Chikungunya and Zika virus</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Chikungunya</condition>
  <condition>Zika</condition>
  <arm_group>
    <arm_group_label>CHIK low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZIKA high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK low dose</intervention_name>
    <description>A single dose of 5x10^9 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_label>CHIK low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK mid dose</intervention_name>
    <description>A single dose of 2.5x10^10 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_label>CHIK mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIK high dose</intervention_name>
    <description>A single dose of 5x10^10 vp ChAdOx1 Chik</description>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_label>CHIK high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA low dose</intervention_name>
    <description>A single dose of 5x10^9 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA low dose</arm_group_label>
    <arm_group_label>ZIKA low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA mid dose</intervention_name>
    <description>A single dose of 2.5x10^10 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA mid dose</arm_group_label>
    <arm_group_label>ZIKA mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZIKA high dose</intervention_name>
    <description>A single dose of 5x10^10 vp ChAdOx1 Zika</description>
    <arm_group_label>CHIK ZIKA high dose</arm_group_label>
    <arm_group_label>ZIKA high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>A single dose of isotonic saline solution (0.9%)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men aged 18 to 50 (inclusive) years at the time of screening.&#xD;
&#xD;
          2. Healthy women aged 18 to 50 (inclusive) of child-bearing potential who agree to&#xD;
             practice continuous effective contraception (see below) during the study and test&#xD;
             negative for pregnancy on the day(s) of screening and vaccination.&#xD;
&#xD;
          3. Are residents of the metropolitan area of Monterrey, Nuevo León.&#xD;
&#xD;
          4. Provide written informed consent for participation in the study.&#xD;
&#xD;
          5. Able and willing (in the Investigator's opinion) to comply with all study&#xD;
             requirements.&#xD;
&#xD;
          6. Agreement to inform study team of any impending vaccinations either before or during&#xD;
             participation in the study.&#xD;
&#xD;
          7. Agreement to refrain from blood donation during the course of the study.&#xD;
&#xD;
          8. Agreement to refrain from receipt of any alphavirus or flavivirus vaccine throughout&#xD;
             the duration of the study (e.g. investigational or licensed Yellow Fever, Japanese&#xD;
             Encephalitis, Tick Borne Encephalitis or Dengue virus vaccines).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical trial in the 30 days preceding enrolment or during&#xD;
             the study period.&#xD;
&#xD;
          2. Prior receipt of an investigational or licensed vaccine likely to impact on&#xD;
             interpretation of the trial data (e.g. Adenovirus vectored vaccine, Chikungunya virus&#xD;
             vaccine, Zika virus vaccine, Dengue virus vaccine).&#xD;
&#xD;
          3. Prior receipt of any vaccines administered ≤30 days before enrolment and/or planned&#xD;
             during the during the study.&#xD;
&#xD;
          4. Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned administration of the vaccine candidate.&#xD;
&#xD;
          5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)&#xD;
             immunosuppressant medication within the past 6 months (inhaled and topical steroids&#xD;
             are allowed).&#xD;
&#xD;
          6. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine. Any history of anaphylaxis in relation to vaccination.&#xD;
&#xD;
          7. History of autoimmune disease.&#xD;
&#xD;
          8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
&#xD;
          9. Pregnancy, lactation or willingness/intention to become pregnant during the study.&#xD;
&#xD;
         10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ).&#xD;
&#xD;
         11. History of serious psychiatric condition likely to affect participation in the study&#xD;
&#xD;
         12. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior&#xD;
             history of significant bleeding or bruising following IM injections or venepuncture.&#xD;
&#xD;
         13. Any other serious chronic illness requiring hospital specialist supervision at present&#xD;
             or during the last 6 months.&#xD;
&#xD;
         14. Suspected or known current alcohol abuse. For men, intake greater than 5 drinks on a&#xD;
             single occasion or more than 15 drinks per week; and for women, more than 4 drinks on&#xD;
             a single occasion or more than 8 drinks per week. One drink =14 grams of pure alcohol.&#xD;
&#xD;
         15. Suspected or known injecting drug abuse in the 5 years preceding enrolment.&#xD;
&#xD;
         16. Seropositive for hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
         17. Seropositive for hepatitis C virus (antibodies to HCV).&#xD;
&#xD;
         18. Any clinically significant abnormal finding on screening biochemistry or haematology&#xD;
             blood tests or urinalysis.&#xD;
&#xD;
         19. Has history of chronic or acute severe neurologic condition. Including: Neurologic and&#xD;
             Neuroinflammatory Disorders: ADEM, including site specific variants, Cranial Nerve&#xD;
             Disorders (including paralyses/paresis), GBS (including Miller Fisher Syndrome and&#xD;
             other variants), Immune-mediated Peripheral Neuropathies and Plexopathies, Optic&#xD;
             Neuritis, Multiple Sclerosis, Narcolepsy, Transverse Myelitis, meningitis, or&#xD;
             meningoencephalitis.&#xD;
&#xD;
         20. Any other significant disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data.&#xD;
&#xD;
         21. Seropositivity or cross-reactivity to Chikungunya virus, Zika virus or Dengue virus on&#xD;
             screening tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abiel Homero Mascareñas de los Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot; Universidad Autónoma de Nuevo León</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo León.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>March 22, 2022</last_update_submitted>
  <last_update_submitted_qc>March 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>ChAdOx1</keyword>
  <keyword>Chikungunya</keyword>
  <keyword>Zika</keyword>
  <keyword>Mexico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04440774
org study id: CHIKA01
nct id: NCT04440774
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise
      dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate
      ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in
      co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan
      area of Monterrey (Mexico), will be recruited as participants
This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1
      Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration,
      and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12
      participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo
      administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered
      contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika
      administered contralaterally. Group 10 will receive placebo in both arms.

      Enrolment into this study will be implemented in a step-wise dose escalation manner.
      Participants will be first recruited into the vaccination groups at the lowest dose (Groups
      1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory
      interim clinical safety reviews that participants will be enrolled into the mid dose groups
      (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be
      enrolled last, after completion and interim clinical safety reviews from the mid dose groups.
      Participants allocated to the Placebo group (Group 10) will be evenly distributed across the
      dose escalation model.

      Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of
      the four intervention arms.

      The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken
      for 6 months after vaccination day

      Innovate UK (project number 971557)
allocation: Randomized
intervention model: Sequential Assignment
primary purpose: Prevention
masking: Double (Participant, Care Provider)
measure: Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of local reactogenicity signs and symptoms
time frame: 7 days post vaccination
description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination.
measure: Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of solicited systemic reactogenicity signs and symptoms
time frame: 7 days post vaccination
description: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.
measure: Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of unsolicited adverse events
time frame: 28 days post vaccination
description: Occurrence of unsolicited adverse events for 28 days following vaccination
measure: Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants through standard blood tests (full blood count, liver and kidney function tests)
time frame: 28 days post vaccination
description: Change from baseline for safety laboratory measures (haematology and biochemistry blood results)
measure: Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of serious adverse events during the whole study duration
time frame: 6 months post vaccination
description: Occurrence of serious adverse events during the whole study duration
measure: Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via PRNT50
time frame: 6 months post vaccination
description: Plaque-reduction neutralisation tests at 50% (PRNT50) against chikungunya and Zika virus.
measure: Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via IgG ELISA antibody titres
time frame: 6 months post vaccination
description: IgG ELISA antibody titres against proteins of Chikungunya and Zika virus
arm group label: CHIK low dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: CHIK mid dose
arm group type: Experimental
description: Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: CHIK high dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: ZIKA low dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: ZIKA mid dose
arm group type: Experimental
description: Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: ZIKA high dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: CHIK ZIKA low dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: CHIK ZIKA mid dose
arm group type: Experimental
description: Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: CHIK ZIKA high dose
arm group type: Experimental
description: Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
arm group label: Placebo
arm group type: Placebo Comparator
description: Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
intervention type: Biological
intervention name: CHIK low dose
description: A single dose of 5x10^9 vp ChAdOx1 Chik
arm group label: CHIK ZIKA low dose
arm group label: CHIK low dose
intervention type: Biological
intervention name: CHIK mid dose
description: A single dose of 2.5x10^10 vp ChAdOx1 Chik
arm group label: CHIK ZIKA mid dose
arm group label: CHIK mid dose
intervention type: Biological
intervention name: CHIK high dose
description: A single dose of 5x10^10 vp ChAdOx1 Chik
arm group label: CHIK ZIKA high dose
arm group label: CHIK high dose
intervention type: Biological
intervention name: ZIKA low dose
description: A single dose of 5x10^9 vp ChAdOx1 Zika
arm group label: CHIK ZIKA low dose
arm group label: ZIKA low dose
intervention type: Biological
intervention name: ZIKA mid dose
description: A single dose of 2.5x10^10 vp ChAdOx1 Zika
arm group label: CHIK ZIKA mid dose
arm group label: ZIKA mid dose
intervention type: Biological
intervention name: ZIKA high dose
description: A single dose of 5x10^10 vp ChAdOx1 Zika
arm group label: CHIK ZIKA high dose
arm group label: ZIKA high dose
intervention type: Biological
intervention name: Saline placebo
description: A single dose of isotonic saline solution (0.9%)
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Abiel Homero Mascareñas de los Santos, MD
role: Principal Investigator
affiliation: Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León
facility: 
country: Mexico
responsible party type: Sponsor
mesh term: Chikungunya Fever